By Torpedo / 24th February, 2024
[Terbium-161] Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lutetium-177]Lu-PSMA-617
Evaluation of alternative radionuclides for use in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on Terbium-161, which may provide advantages by emitting additional Auger and conversion electrons. In this pilot study, we present preliminary dosimetry data for [Terbium-161]Tb-PSMA-617 RLT in a direct comparison with [Lutetium-177]Lu-PSMA-617.
![[Terbium-161] Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lutetium-177]Lu-PSMA-617](https://cms.swissrockets.com/assets/f35608bf-891b-4e08-883f-f74908371012.svg?fit=inside&width=1000&height=1000&quality=100)